Drug Discovery & DDS– category –
-
Immunai and AstraZeneca Expand Oncology AI Partnership for Third Time, Valued at Up To $37.5 Million
WTWH Media USA Overview Immunai, a startup building foundation models for the human immune system, has announced a third expansion of its oncology partnership with AstraZeneca, entitling Immunai to up to $37.5 million through 2027. This ... -
Incyte and Genesis Molecular AI Expand Partnership to Accelerate AI-Driven Drug Discovery with Over $1 Billion in Milestones
Forbes USA Overview Incyte has significantly expanded its strategic collaboration with Genesis Molecular AI, integrating AI platforms with proprietary experimental data to accelerate novel molecule discovery. This enhanced partnership, p... -
Lilly’s Retatrutide Achieves Unprecedented Weight Loss in Pivotal Phase 3 Obesity Trial
Eli Lilly and Company USA Overview Eli Lilly's triple-agonist retatrutide, targeting GIP, GLP-1, and glucagon receptors, demonstrated powerful efficacy in its pivotal Phase 3 TRIUMPH-1 trial for obesity. Patients receiving the highest do... -
Drug Discovery & DDS Weekly Report May 18, 2026
📄 Weekly Report May 18, 2026 (PDF) — Download Weekly Report May 18, 2026 (PDF) — DownloadDownload 🎙 Podcast May 17, 2026 (MP3) — Play & Download DrugDiscovery_DDSEnglishPodcast_20260517_sample.mp3Download -
Daiichi Sankyo Records Significant Loss Due to ADC Supply ‘Miscalculation’ Despite Strong Enhertu Sales, Raising Risk Management Questions
東洋経済オンライン Japan Overview Japanese pharmaceutical giant Daiichi Sankyo reported a substantial operating profit decrease for FY2025 despite record sales, attributing a 169.5 billion yen loss provision to compensation for Antibody-... -
Curanex Pharmaceuticals Reports Q1 2026 Progress, Phyto-N Advances Towards FDA IND Submission for Ulcerative Colitis and Pipeline Expands to Cancer Cachexia
Taiwan News Taiwan Overview US-based Curanex Pharmaceuticals provided a Q1 2026 update, focusing on its lead drug candidate, Phyto-N. The company is advancing Phyto-N towards a planned Investigational New Drug (IND) submission to the U.S... -
Veritas In Silico Advances mRNA-Targeted Small Molecule Drug Discovery with AI Platform ‘aibVIS,’ Bolstering European Collaborations
Investing.com (Fisco提供) Japan Overview Japanese biotech Veritas In Silico (VIS) is spearheading mRNA-targeted small molecule drug discovery using its proprietary AI platform, "aibVIS." This platform integrates in silico RNA structure a... -
Alteogen Secures Domestic Approval for Aflibercept Biosimilar ‘Eygenpiju’ in South Korea, Accelerating Global Reach
Daum South Korea Overview South Korean biopharmaceutical company Alteogen announced domestic market approval from the Ministry of Food and Drug Safety (MFDS) for 'Eygenpiju' (ALT-L9), its aflibercept biosimilar. This approval follows Eur... -
Celltrion Projected to Achieve First Annual Revenue of 5 Trillion Won (approx. $3.4 Billion) Driven by Expanding European Biosimilar Market Share
BigGo Finance South Korea Overview South Korean biopharmaceutical company Celltrion is projected to reach its first-ever annual revenue exceeding 5 trillion won (approximately $3.4 billion) in 2026, buoyed by robust performance in the Eu... -
Avidity Biosciences Leads Muscle Disease Therapy with Antibody-Oligonucleotide Conjugates (AOCs): DM1 HARBINGER™ Trial Advances to Phase 3
Bitget Global Overview Avidity Biosciences is a leading company in Antibody-Oligonucleotide Conjugates (AOCs), developing novel RNA therapeutics for muscle diseases. Its lead candidate, delpacibart etedesiran (AOC 1001), is progressing i...
